Drugs / 111In-XYIMSR-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07062549 | Jan 2022 → Jul 2027 expected | renal cell carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 111In-XYIMSR-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07062549 ↗ |
| Modality | Diagnostic / imaging agent | “investigational radiotracer called 111In-XYIMSR-01” NCT07062549 ↗ |
| Route | Intravenous | “Route of administration: Intravenous catheter placed in an antecubital vein or an equivalent venous access” NCT07062549 ↗ |